Intuitive Surgical (NASDAQ:ISRG) Trading 1.2% Higher - Still a Buy?

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) rose 1.2% during trading on Friday . The company traded as high as $599.07 and last traded at $598.37. Approximately 347,289 shares changed hands during trading, a decline of 80% from the average daily volume of 1,724,817 shares. The stock had previously closed at $591.39.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. CICC Research initiated coverage on shares of Intuitive Surgical in a research report on Monday, January 27th. They set a "neutral" rating and a $550.00 price target on the stock. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a "buy" rating in a research report on Thursday, December 5th. UBS Group boosted their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Finally, Royal Bank of Canada boosted their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $613.10.

Remove Ads

Intuitive Surgical Stock Performance

The business's 50 day simple moving average is $559.48 and its 200-day simple moving average is $520.19. The company has a market cap of $212.12 billion, a price-to-earnings ratio of 92.91, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 108 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company's stock, valued at $4,746,819.42. This represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares of the company's stock, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,348 shares of company stock valued at $3,587,582. 0.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intuitive Surgical

A number of large investors have recently added to or reduced their stakes in ISRG. Atala Financial Inc bought a new stake in Intuitive Surgical during the fourth quarter worth approximately $25,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $26,000. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $26,000. BankPlus Trust Department acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at $28,000. Finally, Hurley Capital LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at $28,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.